Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shock As AstraZeneca’s Oncology R&D Head José Baselga Dies

Executive Summary

AstraZeneca’s CEO Pascal Soriot confirmed the death of distinguished cancer researcher and head of its oncology R&D unit, José Baselga, on 21 March.

You may also be interested in...



Back To The Day Job? AstraZeneca’s Pangalos Looks Ahead To A Post-Pandemic Pipeline

Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.

AZ COVID-19 Vaccine Scores 79% In Pivotal US Trial – Any Hope For A Fresh Start?

The US FDA will now have the full efficacy data that it wanted from AstraZeneca, but the company still has to deal with concerns over safety and global supply issues.

DESTINY Calls For Daiichi Sankyo/AZ’s Enhertu In Other Indications

Daiichi Sankyo and AstraZeneca’s ambitions to expand the use of their HER-2 targeted antibody-drug conjugate product beyond breast cancer are looking realizable on the back of new results presented at ASCO, but toxicities remain an issue. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144037

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel